Actively Recruiting
Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD
Led by Sir Mortimer B. Davis - Jewish General Hospital · Updated on 2025-04-03
70
Participants Needed
1
Research Sites
226 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose : Detect and profile Multiple myeloma Measurable Residual Disease(MRD) prognostics for monitoring post-transplant Multiple Myeloma (MM) Patients receiving maintenance therapy.
CONDITIONS
Official Title
Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed diagnosis of Multiple Myeloma
- Eligible for transplant and currently in first remission
- Known MRD level detected by ClonoSeq or other recognized methods
- Availability of deidentified demographic and clinical follow-up data
- Receiving standard of care treatment
- Able to provide informed consent
You will not qualify if you...
- Failure to meet all inclusion criteria
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Jewish General Hospital
Montreal, Quebec, Canada, H3T 1E2
Actively Recruiting
Research Team
R
Rayan Kaedbey, MD FRCPC
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here